Medicines UK has joined the Geneva-based International Generic and Biosimilar Medicines Association (IGBA) as an Associate Member.
Mark Samuels, Chief Executive of Medicines UK, said: “We are pleased to be joining IGBA and look forward to contributing actively to strengthened global partnerships on the critical issuesaffecting the manufacture and supply of off-patent medicines.
“At a time of heightened global pressures, it is essential for our industry to speak with a unified voice on the challenges facing manufacturers worldwide. IGBA provides an important forum for collaboration, engagement and advocacy, and we look forward to supporting its programme of work.”
“It is a pleasure to welcome Medicines UK as a new member,” said Jim Keon, IGBA Chair.
“Medicines UK is a strong voice for the off-patent medicines industry, helping to build understanding of the role generics and biosimilars play in patient access and healthcare system sustainability. These are goals we share at IGBA, and we look forward to joining forces with Medicines UK in our shared mission of expanding patient access.”
IGBA Secretary General Ana Gaunt said: “We are delighted to welcome Medicines UK to the IGBA community. Medicines UK will strengthen IGBA's work to advance regulatory harmonisation andconvergence, balanced IP systems, resilient supply chains and sustainable markets worldwide, ultimately benefiting patients and healthcare systems everywhere.”
Medicines UK represents the manufacturers and suppliers of nine out of ten of the prescription medicines used by the United Kingdom’s National Health Service (NHS).
